In India, there might be a delay in the availability of the Sputnik V vaccine developed by Russia. The issue arose after the expert committee has adjourned its decision on the application seeking emergency use authorization for the shots. Reportedly, the vaccine is said to have a high interim efficacy of 91.6 percent.
As per sources, the expert committee has asked Hyderabad-based Dr. Reddy’s Laboratories for more data related to stability and a factsheet. Reportedly, it is mandatory to store a variant of the vaccine at a temperature of minus 18 degrees Celsius. Moreover, the company has been asked to submit a clear logistical plan to support the required cold chain and storage.
In February, Dr. Reddy’s Lab had applied for emergency use. However, it was asked to return after completing phase 2 and 3 bridging studies in India.